Department of Hematology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Minamimati 2-1-1, Minatojima, Chuo-ku, Kobe, 650-0047, Japan.
Department of Environmental Medicine and Population Science, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Bone Marrow Transplant. 2023 Feb;58(2):186-194. doi: 10.1038/s41409-022-01871-8. Epub 2022 Nov 14.
A conditioning regimen is an essential prerequisite of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome (MDS). However, the optimal conditioning intensity for a patient may be difficult to establish. This study aimed to identify optimal conditioning intensity (reduced-intensity conditioning regimen [RIC] or myeloablative conditioning regimen [MAC]) for patients with MDS. Overall, 2567 patients with MDS who received their first HCT between 2009 and 2019 were retrospectively analyzed. They were divided into a training cohort and a validation cohort. Using a machine learning-based model, we developed a benefit score for RIC in the training cohort. The validation cohort was divided into a high-score and a low-score group, based on the median benefit score. The endpoint was progression-free survival (PFS). The benefit score for RIC was developed from nine baseline variables in the training cohort. In the validation cohort, the hazard ratios of the PFS in the RIC group compared to the MAC group were 0.65 (95% confidence interval [CI]: 0.48-0.90, P = 0.009) in the high-score group and 1.36 (95% CI: 1.06-1.75, P = 0.017) in the low-score group (P for interaction < 0.001). Machine-learning-based scoring can be useful for the identification of optimal conditioning regimens for patients with MDS.
预处理方案是骨髓增生异常综合征(MDS)患者进行异基因造血干细胞移植的必要前提。然而,确定患者的最佳预处理强度可能具有一定难度。本研究旨在为 MDS 患者确定最佳预处理强度(强度降低的预处理方案[RIC]或清髓性预处理方案[MAC])。总体而言,对 2009 年至 2019 年间接受首次 HCT 的 2567 例 MDS 患者进行了回顾性分析。这些患者被分为训练队列和验证队列。通过机器学习为 RIC 在训练队列中建立获益评分。根据中位获益评分,验证队列被分为高评分组和低评分组。终点为无进展生存(PFS)。RIC 的获益评分是从训练队列中的 9 个基线变量中建立的。在验证队列中,RIC 组与 MAC 组的 PFS 风险比分别为高评分组 0.65(95%置信区间[CI]:0.48-0.90,P = 0.009)和低评分组 1.36(95% CI:1.06-1.75,P = 0.017)(交互检验 P<0.001)。基于机器学习的评分有助于确定 MDS 患者的最佳预处理方案。
Biol Blood Marrow Transplant. 2018-9-19